The refined disease risk index (DRI) is a powerful prognostic model based solely on the disease type and stage for predicting survival outcomes of various hematological malignancies after allogeneic transplant. Here, we analyzed our series of 690 patients transplanted over the past 15 years, and showed that besides overall survival (OS), the refined DRI is also able to segregate event-free survival and relapse mortality in our cohort of largely Southeast Asian patients with a long and complete follow-up. Stratification by refined DRI remains statistically significant even when broken down by specific diseases each with a smaller number of patients, as well as for a small subset of patients younger than 18 years old, providing a robust model for prognostication. Multivariable analysis shows that refined DRI, age, year of transplant and donor type are independent risk factors for OS. We further demonstrated here that prognostication for a given patient with a specific disease can be made more discriminating by integrating independent risk factors such as age and donor type with the refined DRI. The future development of prognostic system incorporating the refined DRI with patient-and transplant-related risk factors will provide a more precise estimate of transplant outcome.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an effective treatment modality for a variety of malignant hematological diseases, but carries a high risk of treatment-related mortality while not completely obviating the risk of relapse. Ability to estimate the risk of relapse and death from treatment is therefore important to provide risk vs benefit considerations for decision-making. Prognostic models have been established over the years based on the patient's health status such as the hemopoietic cell transplantation-specific comorbidity index (HCT-CI) 1 and the more recently proposed comorbidity-age index, 2 as well as models that include disease risk together with the transplant-related factors such as the EBMT risk score. 3 In the last few years, the disease risk index (DRI) was established with a data set of 1539 patients on the sole basis of the combination of a ternary breakdown for disease type and a binary breakdown for remission status to stratify patients into four risk groups, showing significantly different survival outcomes. 4 Recently, this was further refined into the refined DRI with a data set of 13 131 patients from the CIBMTR. 5 This index applies regardless of age, conditioning regimen, donor type and graft source.
The refined DRI 5 has a short follow-up of 2 years, and overall survival (OS) is the only outcome indicator. We are interested to study firstly, whether the refined DRI risk groups can also segregate other survival outcome measures such as the eventfree survival (EFS), relapse and non-relapse mortality (NRM).
Second, we attempt to explore whether the refined DRI in combination with other independent risk factors could provide an individualized estimate for any given patient. Here, we report the results of our patients undergoing allo-SCT from our two centers comprising mainly of Southeast Asian patients with a long and complete follow-up.
definition by the original DRI. 4 Acute leukemia with ambiguous lineage 8 that was not included in the refined DRI prognostic model was excluded.
Statistical analysis
The Kaplan-Meier method was used to estimate cumulative probabilities of OS and EFS, and the log-rank test to analyze statistical significance, using SPSS v21 (Armonk, NY, USA). Median follow-up duration was calculated by reverse Kaplan-Meier method. Cumulative incidence of NRM and cumulative incidence of relapse were estimated by accounting for the other as a competing risk using the stcompet procedure of STATA v13 (College Station, TX, USA) for competing risks analysis. Besides the refined DRI, the role of other well-established prognostic factors including age, year of SCT, conditioning intensity, graft source, donor type, HCT-CI, donor and recipient gender matching, CMV serostatus and CD34+ cell dose were evaluated by univariate and multivariable analysis using Cox's proportional hazards regression analysis for OS and EFS, and Fine and Gray's competing risk regression for cumulative incidence of relapse and cumulative incidence of NRM. Variables significant at a P-value of ⩽ 0.2 on univariate analysis were considered for inclusion in the multivariable analysis. We Abbreviations: HCT-CI = hemopoietic cell transplantation-specific comorbidity index; NA = non-applicable. Table 2 .
Refined DRI is highly predictive of OS for our patients (P o0.001 across strata). This is true even by pairwise comparison, where the difference in OS is also significant (P o 0.001) between all refined DRI pairs except for that between low-and intermediate-risk groups (P = 0.078; Figure 1a ). Table 3a shows the OS for each risk group at 2, 5, 10 and 15 years. As seen from the table, the long-term (up to 15 years) OS for the low-risk group is 61.3% as compared with 49.9% for the intermediate-risk group. In comparison, that for high-risk group is 20% at nearly 10 years. For the very-high-risk group, follow-up duration is much shorter owing to the much higher mortality, such that OS is 5.2% at the longest follow-up of 48 months.
Not surprisingly, refined DRI is also highly predictive of EFS (P o 0.001) and the pattern closely follows that for OS ( Figure 1b) . EFS is significantly different between all pairs (P o 0.001) except for that between low-and intermediate-risk groups (P = 0.256; Figure 1b ). As seen in Table 3a , the EFS up to 15 years for the low-and intermediate-risk groups are 49.8% and 41.7%, respectively. On the other hand, EFS for high-risk group is 19.2% at 5 years and only 8.70% for the very-high-risk group at 2 years.
We then analyzed the impact of refined DRI on relapse and NRM. As expected, the cumulative incidence of relapse increases progressively across the four refined DRI risk groups. Refined DRI has an impact on cumulative incidence of NRM too. Although cumulative incidence values between low-and intermediate-risk groups are comparable, cumulative incidence of NRM is higher for the high-risk group and even higher for the very-high-risk group, being 32% and 43%, respectively at 2 years ( Figure 1d and Table 3a ).
The great impact of refined DRI on OS, EFS, relapse and NRM can be further appreciated by the overall highly significant hazard ratios (HRs) compared with the low-risk group by univariate analysis (Table 4) . Although there is no significant difference in the OS, EFS and relapse risk between intermediate-and low-risk groups, this is significantly higher for the high-and very-high-risk groups as compared with the low-risk group. For NRM, again we noted that the very-high-risk group has a significant impact, being 2.13-fold (95% confidence interval: 1.13-4.01) that of the low-risk group (Table 4) .
Risk allocation in refined DRI for specific diseases is accurate The refined DRI incorporates many different diseases at different stages into four risk categories. We explored whether the risk stratification is applicable to each of the four most commonly transplanted diseases AML, ALL, CML and MDS, by analyzing the OS and EFS as classified by the refined DRI (Table 3b) . We found that the OS and EFS curves of the DRI-defined risk groups for each disease are remarkably comparable (Figures 2a-d for OS and Supplementary Figure 1 for EFS). In fact, the OS curves for each refined DRI group of each of these four diseases are almost superimposable, with difference not exceeding 5% (Figures 2a-d and Table 3b ). The same applies to EFS (Supplementary Figure 1 and Table 3b ). This observation supports the accuracy of risk group assignment in the refined DRI prognostic model. Refined DRI is applicable to patients o 18 years of age The original DRI and the refined DRI included only patients 18 years and above. In our series, we have 22 patients aged between 12 and 17 years old. When analyzed for their OS and EFS based on the refined DRI, the difference in survival is also highly significant (P o 0.001 across strata; Supplementary Figure 2) . On the basis of pairwise comparison by log-rank test, there is no significant difference between the high-and very-high-risk groups, nor between the low-and intermediate-risk groups, but the difference is significant for the high-and very-high-risk groups vs intermediate-and low-risk groups. Abbreviations: CINRM = cumulative incidence of NRM; CIR = cumulative incidence of relapse; DRI = disease risk index; EFS = event-free survival; NA = not applicable; NRM = non-relapse mortality; OS = overall survival. Abbreviations: DRI = disease risk index; EFS = event-free survival; NA = not available as the longest follow-up has not reached that time point; none = no such risk group designated for the disease in the refined DRI; OS = overall survival.
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Refined DRI remains predictive independent of other transplant-related factors In addition to the refined DRI, other patient-and transplantrelated factors that are known to impact transplant outcome were analyzed in univariate (Table 4 ) and multivariable (Table 5) analyses. As expected, besides refined DRI, other factors such as older age, alternative donor (cord blood and haploidentical), female donor to male recipient and higher HCT-CI have a significant adverse impact on OS in univariate analysis. In addition to the above, earlier period, reduced intensity conditioning transplant (RICT)/non-myeloablative condition (MAC) regimen and graft source also significantly affect EFS. For relapse, earlier period and RICT/non-MAC transplants are significant risks, whereas for NRM, older age, earlier period, alternative donor, higher HCT-CI and female donor to male recipient are significant risks, in addition to refined DRI. CMV serostatus of donor/recipient pair and CD34 dose have no impact on OS, EFS or relapse.
In multivariable analysis, refined DRI remains a significant factor for OS, EFS and relapse, but not for NRM (Table 5 ) among the other risk factors. Besides refined DRI, independent risk factors for OS include age, earlier period and alternative donors, where the first two are also independent risk factors for EFS. In terms of risk of relapse, besides higher refined DRI, RICT/non-MAC regimen gives a risk of relapse that is 1.52-fold that of MAC transplant. For Abbreviations: CI = confidence interval; DRI = disease risk index; EFS = event-free survival; HCT-CI = hemopoietic cell transplantation-specific comorbidity index; HR = hazard ratio; MAC = myeloablative condition; NRM = non-relapse mortality; OS = overall survival; RIC = reduced intensity conditioning; SHR = subdistribution hazard ratio. Those P-values that are o 0.05 are in bold.
NRM, it is not surprising that the well-known risks such as older age, earlier period, alternative donor and transplants with female donor to male recipient are independent risks for higher mortality. The refined DRI loses its impact on NRM, even for the very-high-risk group.
Refined DRI together with other independent risk factors provides further individualized risk stratification In the real-life situation for a given patient, the purpose of the prognostic models is to give a more specific outcome prediction for his/her particular disease. We explore here whether the prognostication for an individual patient may be further refined by incorporating the independent risk factors such as year at HSCT, age and donor type as verified from the multivariable analysis in addition to the refined DRI. For example, a patient of any age with low DRI risk undergoing matched-sibling transplant has a long-term probability of survival of 68.8% at 182 months (n = 51).
In contrast, a high-or very-high-DRI risk patient undergoing a haploidentical or cord blood transplant has a predicted long-term OS of only 14.8% at 90 months (n = 35; Figure 3a) . For a specific disease such as AML (n = 301), the OS for an intermediate DRI patient with AML undergoing transplant with a sibling/unrelated donor is 57.9% for the age group o50 years old and 42.5% for 50 years or older (P = 0.032, Figure 3b ). When an AML patient younger than 50 years with intermediate DRI undergoes transplant, the OS is not different (P = 0.562) between a conventional (matched sibling or unrelated) donor vs alternative donor (Figure 3c ). However, for the patient aged 50 years and above, his long-term OS with a conventional donor is estimated to be 42.5%, as compared with~25% for an alternative-donor transplant (P = 0.077, Figure 3d ). Analysis like this will be possible for diseases with large enough number for subgroup analysis and will provide a more precise estimate than using the refined DRI alone.
DISCUSSION
Estimation of survival outcome is a critical consideration for every patient going for allo-HSCT. Several groups have validated their retrospective series with the original DRI 9,10 or refined DRI, [11] [12] [13] and confirmed its predictive value even for specific transplant protocols such as T-cell depleted 9 and haploidentical transplants. 11 In our series of 690 patients, we showed that refined DRI applies equally well to our patient cohort, with 2-year OS of 71.30%, 59.10%, 30.20% and 10.40% for the low-, intermediate-, high-and very-high-risk groups, comparable to the original refined DRI series 5 of 66%, 51%, 33% and 23%, respectively, which further supports the applicability of the refined DRI in a population of a different ethnicity. The refined DRI segregates EFS equally well. In the long term, we show that both OS and EFS for the low-, intermediate-and high-risk groups drop by approximately another 10% after the first 2 years, stabilizing at 10 years and beyond (Figures 1a and b, Table 3a) . The difference between the low-and intermediate-risk groups in pairwise comparison did not reach statistical significance by log-rank test, with a 1.48-fold (95% confidence interval: 0.96-2.28) higher risk in OS in the intermediate-risk group, likely owing to the disproportionally large number in the intermediate-risk group (n = 431, 62.46%) in contrast to the small number in the low-risk group (n = 69, 10%), which in fact recapitulates the original published series that was 63% and 14%, respectively. The large number in the intermediate-risk group that includes 17 heterogeneous disease/stage categories (12 in our series) inevitably compromise the segregating power of this model. This also implies that there may be room for further refinement within this group. As OS and EFS are direct results of NRM and relapse, we are not surprised to find that relapse and NRM can be similarly segregated by refined DRI in univariate analysis. The published refined DRI model was not analyzed on EFS, relapse and NRM, whereas the original DRI 4 showed impact on EFS and relapse, but not NRM. In contrast, we found that the refined DRI also impact on NRM, specifically, the very-high-risk group had a 2.13-fold higher risk of NRM than low-and intermediate-risk groups (P = 0.018) in univariate analysis. This was lost in multivariable analysis owing to multiple other independent factors for NRM overshadowing the impact of refined DRI. After all, refined DRI only stratifies disease-related characteristics that primarily impact on relapse risk rather than NRM.
The refined DRI model advised simplification to a three-group breakdown by merging the very-high-risk and high-risk groups for a cohort size of 300 or smaller. In our OS and EFS analysis for AML (n = 301) that is stratified into four groups, as well as for ALL (n = 150) and CML (n = 65) that are stratified into three groups based on the definition of refined DRI, and MDS (n = 67) that is stratified into only intermediate-and high-risk groups, all can be well segregated in their OS (Figures 2a-d) and EFS (Supplementary Figure 1) . Similarly, although the original DRI and refined DRI were both developed on patients 18 years and older, separate analysis of our small subset of 22 patients who are younger than 18 years still demonstrates significant difference between the low-/intermediate-vs the high-/very-high-risk groups (Supplementary Figure 2) . These findings testify to the robustness of the refined DRI model in segregating risk groups.
Similar to that reported, we find that the refined DRI remains an independent risk factor in multivariable analysis, among the other well-established risk factors. The other independently significant risk factors are logical and expected. Older age and earlier period are significant risk factors for NRM, which then explains their independent significance for OS and EFS. For conditioning intensity, a less intense regimen is associated with higher relapse and therefore lower EFS than MAC regimen. Alternative donor, as expected, gives a poorer OS owing to its significantly higher NRM. It is interesting that the HCT-CI that is a significant risk in univariate analysis for NRM, therefore OS and EFS, loses its impact in multivariable analysis. This can be explained by the multiple other factors interacting with HCT-CI, such as age, bias in choice of conditioning regimen and even the refined DRI, as patients with higher refined DRI may enter transplant with more comorbidities, such that HCT-CI loses its independent impact on NRM when Abbreviations: CI = confidence interval; DRI = disease risk index; EFS = event-free survival; HCT = hemopoietic cell transplantation; HR = hazard ratio; MAC = myeloablative condition; NRM = non-relapse mortality; OS = overall survival. Those with Po0.05 are in bold.
these other factors are considered in combination. For gender matching, the established risk of female donor to male recipient is clearly shown here, with significantly lower OS and EFS owing to a higher NRM that retains its significance in multivariable analysis. With the above observations that multiple risk factors coexist with the refined DRI in survival outcomes, it logically follows that the risk for any given patient is a composite outcome of all these factors considered together. We have shown here that even for our relatively small number of patients in specific subsets, combination of two or three independent risk factors (specific disease, age group and donor type) together with refined DRI is still possible, and provides a more precise and individualized prognostication. By incorporating the donor type with refined DRI, it defines a 'very-poor-risk' group with high/very high DRI undergoing an alternative-donor transplant that contrasts with a 'very-good-risk' group with low DRI undergoing a sibling-donor transplant. The further refinement in risk stratification for the AML patient by a combination of age, DRI risk and donor type in various scenarios may not be discriminant enough to give good individual prognostication, but it is one step toward increasing the stratification power. A much larger number in the cohort with inclusion of more independent prognostic factors may provide a more refined prognostic power for an individual. Such an approach has also been explored by others who integrated HCT-CI with refined DRI, showing that within each refined DRI risk group, OS can be further segregated for the low (0-2) and high HCT-CI (above 2) subsets. 13 In another report in haploidentical transplant, the 2-year OS for the low/intermediate refined DRI patients with HCT-CI of 0-4 was 64% in contrast to 0% in those with HCT-CI of 5 and above, whereas that for patients with high/very high DRI but HCT-CI of 0-4 was 29%. 12 In summary, we have reaffirmed here the findings of others: the strong prognostic value of the refined DRI for survival outcomes after allo-SCT, including its impact on NRM, in a cohort of Southeast Asian patients followed up for a long period. We have also demonstrated that the incorporation of other patient-and transplant-related prognostic factors with the refined DRI to further improve the prognostication is possible. Such an all-encompassing model will be invaluable for decision-making as well as comparison of treatment outcome across different centers.
